Scott Riccio

Scott Riccio serves as the Head of Patient Advocacy at Karyopharm Therapeutics Inc. since July 2022, focusing on integrating patient perspectives in key disease areas such as Multiple Myeloma and Endometrial Cancer. Previous roles include Executive Vice-President of Patient & Community Engagement at a Stealth Biotech Startup, Head of Advocacy at Myovant Sciences, and head positions at Alder Biopharmaceuticals Inc., Juno Therapeutics, Food Allergy Research & Education, Synageva BioPharma Corp., The Leukemia & Lymphoma Society, Dendreon, and Morningstar Associates, LLC. Scott holds an MBA from The University of Chicago Booth School of Business and a BA in Political Science from Middlebury College, bringing extensive experience in patient engagement, advocacy strategy, and cross-functional leadership across the biopharma and non-profit sectors.